Physician profile
James Michael Tsai
NPI 1356329494
$1,050.48
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $218 · 2021: $192 · 2022: $195.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $248.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $123.04 | 2019-2021 | |
| Pfizer INC. | $100.04 | 2020-2022 | |
| Hologic Sales and Service, LLC | $94.31 | 2019-2021 | |
| Coopersurgical, INC. | $86.59 | 2019-2021 | |
| Allergan, INC. | $74.27 | 2019-2020 | |
| Channel Medsystems, INC. | $49.49 | 2022 | |
| Therapeuticsmd, INC. | $48.01 | 2019-2020 | |
| Myovant Sciences INC. | $40.45 | 2022 | |
| Aspira Women'S Health INC | $35.57 | 2019 | |
| Daiichi Sankyo INC. | $32.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.38 | 2020 | |
| Medtronic USA, INC. | $21.31 | 2019 | |
| Lilly USA, LLC | $17.53 | 2019 | |
| Organon LLC | $15.76 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $14.77 | 2021 | |
| Evofem Biosciences, INC. | $12.90 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.